Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, 249203, India.
Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, 249203, India; Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh 462020, India.
Cancer Treat Res Commun. 2023;36:100750. doi: 10.1016/j.ctarc.2023.100750. Epub 2023 Jul 28.
The global health landscape has experienced a shift towards non-communicable diseases, with cardiovascular diseases and cancer as leading causes of mortality. Although advancements in healthcare have led to an increase in life expectancy, they have concurrently resulted in a greater burden of chronic health conditions. Unintended consequences of anticancer therapies on various tissues, particularly the cardiovascular system, contribute to elevated morbidity and mortality rates that are not directly attributable to cancer. Consequently, the field of cardio-oncology has emerged to address the prevalence of CVD in cancer survivors and the cardiovascular toxicity associated with cancer therapies. Non-coding RNAs (ncRNAs) have been found to play a crucial role in early diagnosis, prognosis, and therapeutics within the realm of cardio-oncology. This comprehensive review evaluates the risk assessment of cancer survivors concerning the acquisition of adverse cardiovascular consequences, investigates the association of ncRNAs with CVD in patients undergoing cancer treatment, and delves into the role of ncRNAs in the diagnosis, treatment, and prevention of CVD in patients with a history of anti-cancer therapy. A thorough understanding of the pathogenesis of cancer therapy-related cardiovascular disease and the involvement of ncRNAs in cardio-oncology will enable healthcare professionals to provide anticancer treatment with minimized cardiovascular side effects, thereby improving patient outcomes. Ultimately, this comprehensive analysis aims to provide valuable insights into the complex interplay between cancer and cardiovascular diseases, facilitating the development of more effective diagnostic, therapeutic, and preventive strategies in the burgeoning field of cardio-oncology.
全球健康格局已经向非传染性疾病转移，心血管疾病和癌症是主要的死亡原因。尽管医疗保健的进步导致了预期寿命的延长，但它们也导致了更多慢性健康状况的负担。抗癌疗法对各种组织的不良影响，特别是心血管系统，导致发病率和死亡率升高，这些并不是癌症直接导致的。因此，出现了肿瘤心脏病学领域来解决癌症幸存者中 CVD 的流行问题，以及与癌症治疗相关的心血管毒性问题。非编码 RNA（ncRNA）已被发现在心肿瘤学领域的早期诊断、预后和治疗中发挥着关键作用。本综述评估了癌症幸存者在获得不良心血管后果方面的风险评估，调查了 ncRNA 与癌症治疗患者 CVD 之间的关联，并探讨了 ncRNA 在癌症治疗史患者的 CVD 诊断、治疗和预防中的作用。深入了解癌症治疗相关心血管疾病的发病机制以及 ncRNA 在肿瘤心脏病学中的作用，将使医疗保健专业人员能够在提供抗癌治疗时尽量减少心血管副作用，从而改善患者的预后。最终，这项全面的分析旨在深入了解癌症和心血管疾病之间的复杂相互作用，为新兴的肿瘤心脏病学领域的更有效诊断、治疗和预防策略的发展提供有价值的见解。
